SCHEMBL7611136

SCHEMBL7611136

CCOC(=O)C(C(=O)O)N(Cc1ccc(-n2cccc2)cc1)C(C)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 6/20 0.45
ALDH1A1 P00352 4/20 0.45
LMNA P02545 4/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
HSD17B10 Q99714 1/20 0.45
NSD2 O96028 1/20 0.43
GRK2 P25098 1/20 0.43
CASP6 P55212 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
AOC2 O75106 2/20 0.41
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
RECQL P46063 2/20 0.38
BLM P54132 1/20 0.38
MCL1 Q07820 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6774510 0.94 ALDH1A1 (0.45) POLBALDH1A1LMNAL3MBTL1HSD17B10
SCHEMBL27475763 0.79 L3MBTL1 (0.60) POLBALDH1A1LMNAL3MBTL1HSD17B10
SCHEMBL6776659 0.76 MAPT (0.42) POLBALDH1A1LMNAL3MBTL1HSD17B10
SCHEMBL6782412 0.74 LMNA (0.45) POLBALDH1A1LMNAL3MBTL1HSD17B10
SCHEMBL6774973 0.72 RAB9A (0.43) POLBALDH1A1LMNAL3MBTL1HSD17B10
SCHEMBL11600743 0.71 MAPT (0.48) ALDH1A1LMNAHSD17B10MAPTSMN1; SMN2
SCHEMBL7619436 0.71 NSD2 (0.44) POLBALDH1A1LMNAL3MBTL1HSD17B10
SCHEMBL6781095 0.71 ALDH1A1 (0.42) POLBALDH1A1LMNAL3MBTL1HSD17B10
SCHEMBL7611167 0.71 ALDH1A1 (0.44) POLBALDH1A1LMNAL3MBTL1NSD2
SCHEMBL14786664 0.70 ALDH1A1 (0.55) POLBALDH1A1LMNAL3MBTL1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020142947-A1 STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS AVENTIS PHARMA, S.A. 2002-10-03 US disclosed
US-6352839-B1 PREPARING VIRGINIAMYCINS FROM AN ENGINEERED MICROORGANISMS, HAVING THE ABILITY TO PREVENT BIOSYNTHESIS OF THE PRECURSOR ANTIBIOTIC; THE MICROORGANISM IS CULTURED IN THE PRESENCE OF A SECOND PRECURSOR AND THE STREPTOGRAMIN ANALOG IS RECOVERED AVENTIS PHARMA S.A. (FR) 2002-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020142947-A1 STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS EMG1, FBL, SMS POLB 38/4885ALDH1A1 3856/4885LMNA 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.